NCT05144997
Lorlatinib Continuation Study
At risk: Primary completion moved at least 2 years 9 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 24 versions: 23 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Dec 28, 2026 to Oct 25, 2029
- Site details revised at 3 of 27 sites
- Minor Enrollment target: 74 to 76
- Study sites: 35 to 27
- Minor Enrollment target: 73 to 74v21
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 200 to confirmed 73
- Study sites revised (35)
- Minor Study sites: 33 to 35v19
Show 17 earlier versionsHide 17 earlier versions
- Minor Study sites: 31 to 33v18
- Minor Study sites: 30 to 31v17
- Minor Study sites: 28 to 30v16
- Minor Site details revised at 2 of 28 sitesv15
- Minor Study sites: 20 to 28v14
- Minor Study sites: 17 to 20
- Primary and study completion dates: Jun 12, 2027 to Dec 28, 2026
- Minor Study sites: 10 to 17
- Primary and study completion dates: Dec 28, 2026 to Jun 12, 2027
- Minor Site details revised at 1 of 10 sitesv11
- Minor Study sites: 9 to 10v10
- Minor Study sites: 8 to 9v9
- Minor Study sites: 7 to 8v8
- Minor Study sites: 6 to 7v7
- Minor Study sites: 4 to 6v6
- Minor Study sites: 3 to 4
- Eligibility criteria shortened, about 19 words
- Minor Site details revised at 1 of 3 sitesv4
- Minor Study sites: 1 to 3v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Primary and study completion dates: Dec 31, 2026 to Dec 28, 2026
- Start date changed from estimate of Dec 31, 2021 to Dec 28, 2021
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of participants with adverse events leading to permanent discontinuation of study intervention
Timeframe: Baseline up to approximately 5 years
Number of serious adverse events reported for all participants
Timeframe: Baseline up to approximately 5 years
Arms and interventions
LorlatinibExperimental
Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
Drugs: Lorlatinib
Sites
27 sites in 8 countries
China 17, France 2, India 2, Singapore 2, Japan 1, Spain 1, Taiwan 1, United States 1